Aclaris Therapeutics, Inc. ACRS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-18.21
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $7.8M | -$64.9M | — | -$47.2M | $103.1M |
| 2024 | $18.7M | -$132.1M | — | -$20.2M | $155.6M |
| 2023 | $31.2M | -$88.5M | — | -$79.6M | $157.2M |
| 2022 | $29.8M | -$86.9M | — | -$68.2M | $197.6M |
| 2021 | $6.8M | -$90.9M | — | -$52.4M | $197.3M |
| 2020 | $6.5M | -$51.0M | — | -$39.1M | $37.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Mehra Anand | director | 2026-06-05 | Option exercise | 11,580 | — |
| SCHIFF ANDREW N | director | 2026-06-05 | Option exercise | 11,580 | — |
| Humphries William D. | director | 2026-06-05 | Option exercise | 11,580 | — |
| Molineaux Christopher P. | director | 2026-06-05 | Option exercise | 11,580 | — |
| MILANO VINCENT | director | 2026-06-05 | Option exercise | 11,580 | — |
| GOWEN MAXINE | director | 2026-06-05 | Option exercise | 11,580 | — |
| Hall Jesse Wayne | Chief Medical Officer | 2026-05-01 | Option exercise | 36,375 | — |
| Hall Jesse Wayne | Chief Medical Officer | 2026-05-01 | Tax withheld | 9,330 | $4.41 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -18.21 (distress)
- Working capital / assets 0.422
- Retained earnings / assets -6.031
- EBIT / assets -0.476
- Equity / liabilities 1.797
Source: SEC EDGAR filings · CIK 0001557746 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.